Telix Pharmaceuticals Ltd. (TLX) witnessed a remarkable surge of 9.88% in its stock price during the pre-market trading session on Friday. This upward movement can be attributed to the company's stellar financial performance for the fiscal year 2024, as reported in its recent earnings call.
Telix Pharmaceuticals demonstrated an impressive 56% year-over-year increase in revenue, surpassing its guidance. The company's adjusted EBITDA saw a substantial 70% improvement, reaching $99 million, reflecting its operational efficiency and profitability. Furthermore, Telix Pharmaceuticals reported an 80% improvement in operating cash inflow, showcasing its strong cash generation capabilities.
One of the most notable achievements was the staggering 860% increase in profit after tax, highlighting the company's ability to convert revenue into substantial profitability. Telix Pharmaceuticals ended the fiscal year with a robust cash position of $710 million, bolstered by a strategic convertible bond placement, providing ample liquidity for future growth initiatives and investments in its therapeutic pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.